You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu

News

NRG receives £2.68m funding boost for neurodegenerative disorders

Neuroscience company NRG Therapeutics has announced that it has received a Biomedical Catalyst award. The £2.68m package will fund the pre-clinical development of its novel small molecule disease-modifying medicines for treating Parkinson’s disease, motor neurone disease (MND) and other debilitating neurodegenerative disorders.